Hematopoietic Cell Patents (Class 424/173.1)
  • Patent number: 10494433
    Abstract: Provided are methods for clinical treatment of multiple myeloma using an anti-KIR antibody in combination with an anti-CS 1 antibody.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: December 3, 2019
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, Innate Pharma
    Inventors: Pascale Andre, Mathieu Blery, Cecile Bonnafous, Ashok K. Gupta, Luisa M. Salter-Cid, Michael Darron Robbins
  • Patent number: 10441810
    Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: October 15, 2019
    Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Harold Walder, Frederic A. Bourke, Jr., Mark Dewhirst, Neil L. Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada
  • Patent number: 10428136
    Abstract: The present invention relates to chimeric antigen receptors (CARs) specific to ICAM-1 comprising I domain of the ?L subunit of human lymphocyte function-associated antigen 1 (LFA-1). The invention particularly relates to CARs comprising human I domains having different affinities (1 mM to 1 nM Kd) to ICAM-1. CAR T cells comprising human I domain having a low affinity (1 to 200 ?M Kd) to ICAM-1 can avoid targeting healthy tissues with basal ICAM-1 expression while simultaneously exhibiting increased potency and long-term efficacy against tumor tissues with high ICAM-1 expression. The present invention also relates to an adoptive cell therapy method for treating cancer by administering the CAR-T cells comprising human I domain to a subject suffering from cancer, whereby the CAR T cells bind to the cancer cells overexpressing ICAM-1 and kill the cancer cells.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: October 1, 2019
    Assignee: Cornell University, Center for Technology Licensing (“CTL”)
    Inventor: Moonsoo Jin
  • Patent number: 10407471
    Abstract: The present invention relates to a composition for preventing, improving, or treating aging, wherein the composition comprises a recombinant protein of flagellin, which is the constituent of Vibrio vulnificus flagella, fused with a pathogenic protein antigen, as an active component. According to the present invention, the recombinant protein of the present invention can improve external and internal aging-related malfunctions and enhance immunity. Also, the composition of the present invention can easily perform immunization through mucosal administration.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: September 10, 2019
    Assignee: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
    Inventors: Kyung A. Cho, Jae Sung Lim, Joon Haeng Rhee
  • Patent number: 10339274
    Abstract: Contemplated antiviral/cancer treatments comprise analysis of neoepitopes from viral DNA that has integrated into the host genome, and design of immunotherapeutic agents against such neoepitopes.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: July 2, 2019
    Assignee: NANTOMICS, LLC
    Inventors: Andrew Nguyen, Stephen Charles Benz, John Zachary Sanborn
  • Patent number: 10106618
    Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: October 23, 2018
    Assignee: ALS Therapy Development Institute
    Inventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
  • Patent number: 10000566
    Abstract: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: June 19, 2018
    Assignee: IMMUNOGEN, INC.
    Inventors: Mary G. Hoffee, Daniel Tavares, Robert J. Lutz
  • Patent number: 9725519
    Abstract: The present invention provides a prophylactic or therapeutic agent for various malignant tumors, including currently intractable solid tumors, which contains an antibody having the ability to bind to human LAT1/CD98 and inducing antibody-dependent cellular cytotoxicity specifically against cancer cells as an active ingredient.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: August 8, 2017
    Assignees: Kinki University, Link Genomics, Inc.
    Inventors: Takashi Masuko, Shinichiro Niwa, Hidemi Hayashi, Dai Ogura, Takayuki Shindou
  • Patent number: 9725501
    Abstract: The present invention provides a method for concentrating a protein, in particular a method for concentrating a plasma product, in particular IgG, using glycine in a two-stage ultrafiltration/diafiltration approach.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: August 8, 2017
    Inventors: Martin Gonzalez, Woody D. Wood, Fred H. Earp
  • Patent number: 9658226
    Abstract: A quantitative method for diagnosing an autoimmune disease or an infectious disease comprising performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex, wherein the capture reagent is a biotinylated autoantigen or infectious disease antigen; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: May 23, 2017
    Assignee: Hycor Biomedical, LLC
    Inventors: Mark David Van Cleve, Elaine Grace Taine, Douglas John Canfield, Stephanie TuVi Ortega, Taylor Addison Reid
  • Patent number: 9657102
    Abstract: The present invention provides antibodies that bind to CD3 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human CD3 with high affinity and induce human T cell proliferation. The invention includes antibodies that bind CD3 and induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human CD20. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell tumors expressing CD20. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: May 23, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric Smith, Nicholas J. Papadopoulos
  • Patent number: 9658225
    Abstract: A quantitative method for performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: May 23, 2017
    Assignee: Hycor Biomedical, LLC
    Inventors: Mark David Van Cleve, Taylor Addison Reid, Linda Marie Trondle, Victoria Hung, Yi Luo, Dennis Edwin Rieger, Evan Phillip McMenamy, Nanditha Raghavan, Morkoah Blay Reliford, Douglas John Canfield, Elaine Grace Taine, Edsel Lawrence Noche Sinson, Scott William Vande Wetering, Teri Taylor, Travis Knox, Fran Zylo Cuaresma Jacalne, James Weston, Jennifer Bao-Guey Chan, Stephanie TuVi Ortega, Rachel Sarah Schell, Ronald Norman Diamond, Steve Michael Gann, Eric Darnell Hall, Tae Ho Hwang, John Lewis Morton, Anatoly Moskalev, Marinela Gombosev Stack, Bruce Alan Sargeant, Michelle Fredrika Forshager, Vanessa Camille Chua, Kylie Wilson
  • Patent number: 9651550
    Abstract: A quantitative method for diagnosing an autoimmune disease or an infectious disease comprising performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex, wherein the capture reagent is a biotinylated autoantigen or infectious disease antigen; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: May 16, 2017
    Assignee: Hycor Biomedical, LLC
    Inventors: Mark David Van Cleve, Elaine Grace Taine, Douglas John Canfield, Stephanie TuVi Ortega, Taylor Addison Reid
  • Patent number: 9457052
    Abstract: A method inducing chimerism and allograft tolerance by co-infusion of stem/progenitor-like cells and donor cells, wherein the donor cells can be bone marrow cells. The method also comprises the conditioning comprising depletion of CD4+ and CD8+ T-cells and administration of low doses of anti-neoplastic drugs. The inventive method comprises an aspect wherein allograft tolerance is induced without systemically suppressing the immune system.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 4, 2016
    Assignee: The United States of America as Represented by the Secretary of the Navy
    Inventors: Thomas A. Davis, Khairul Anam, Eric A. Elster, Douglas K. Tadaki
  • Patent number: 9273141
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: March 1, 2016
    Assignee: Glaxo Group Limited
    Inventors: Paul Algate, Stephanie Jane Clegg, Jennifer L. Craigen, Paul Andrew Hamblin, Alan Peter Lewis, Patrick Mayes, Radha Shah Parmar, Trevor Anthony Kenneth Wattam
  • Patent number: 9260520
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: February 16, 2016
    Assignees: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James McGivney, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • Patent number: 9244075
    Abstract: The present invention provides compositions and methods useful for diagnosing, treating, and preventing cancer, particularly ovarian cancer and uterine cancer, based on the discovery that the oocyte specific protein, SAS1R (Sperm Acrosomal SLLP1 Receptor), which is a sperm protein receptor, is also expressed in various cancers, including ovarian cancer and uterine cancer. Six SAS1R variants have been previously identified, and they are encompassed by the invention. The present invention further provides antibodies useful for targeting SAS1R expressing cells and for killing such cells.
    Type: Grant
    Filed: August 8, 2011
    Date of Patent: January 26, 2016
    Assignee: University of Virginia Patent Foundation
    Inventors: John C. Herr, Euseblo S. Pires
  • Publication number: 20150147344
    Abstract: The invention relates to BTLA antibodies that block BTLA-HVEM interaction and uses thereof.
    Type: Application
    Filed: November 21, 2014
    Publication date: May 28, 2015
    Inventor: Daniel Olive
  • Publication number: 20150140017
    Abstract: The present invention relates to predictors of a cancer patient's responsiveness to immunotherapy for cancer.
    Type: Application
    Filed: March 8, 2013
    Publication date: May 21, 2015
    Inventors: Madhav Dhodapkar, Kavita Dhodapkar
  • Publication number: 20150132290
    Abstract: The invention provides methods and compositions for administration of allogeneic lymphocytes as an an exogenous source of CD4+ T cell help for endogenous, tumor-reactive CD8+ T cells. Depletion of CD8+ T cells from the donor lymphocyte infusion reduces the risk of sustained engraftment and graft-versus-host disease. Removal of regulatory T cells from the infused population may augment the ability of non-regulatory T cells to provide help for endogenous effectors of anti-tumor immunity. Allogeneic T cell therapy is typically given in the context of allogeneic stem cell transplantation, in which the patient receives highly immunosuppressive conditioning followed by an infusion of a stem cell graft containing unselected populations of mature T cells. In the treatment described here, the graft is engineered to minimize the possibility of sustained donor cell engraftment, and the anti-tumor effector T cells derive from the host.
    Type: Application
    Filed: March 15, 2013
    Publication date: May 14, 2015
    Inventors: Ephraim Joseph Fuchs, Heather Jills Symons, Lode Swinnen
  • Publication number: 20150132255
    Abstract: The present invention relates to novel combinations of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel combinations of (1) therapeutic agents which can effect stabilisation of a complex between domains in certain HIV proteins with (2) HIV-specific vaccine peptides.
    Type: Application
    Filed: June 6, 2013
    Publication date: May 14, 2015
    Applicant: Bionor Immuno AS
    Inventors: Birger Sorensen, Mats Okvist, Arnt Ove Hovden, Maja Sommerfelt Gronvold, Lars Hoie, Anker Lundemose, Vidar Wendel Hansen
  • Patent number: 9028826
    Abstract: Improved anti-CD154 antibodies are provided herein which have ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: May 12, 2015
    Assignee: The Trustees of Dartmouth College
    Inventor: Randolph J. Noelle
  • Publication number: 20150125470
    Abstract: Provided is a pharmaceutical composition for the treatment and/or prophylaxis of abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.
    Type: Application
    Filed: March 29, 2013
    Publication date: May 7, 2015
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Yoshiharu Hiruma, Jun Hasegawa
  • Publication number: 20150125447
    Abstract: The present invention relates to pharmaceutical combinations CD33 antibodies and de-methylating agents for use in treating diseases like MDS and cancer, especially AML.
    Type: Application
    Filed: November 5, 2014
    Publication date: May 7, 2015
    Inventor: Karl-Heinz HEIDER
  • Publication number: 20150118252
    Abstract: Antigen binding constructs that bind to CD3, for example antibodies, including antibody fragments (such as minibodies and cys-diabodies) that bind to CD3, are described herein. Methods of use are described herein.
    Type: Application
    Filed: June 13, 2013
    Publication date: April 30, 2015
    Inventors: David T. Ho, Tove Olafsen, Jason Romero, Christian P. Behrenbruch
  • Patent number: 9017682
    Abstract: Methods, uses, agents and compositions useful for the diagnosis, prevention and/or treatment of inflammatory conditions, such as neuroinflammatory conditions such as multiple sclerosis, and for the identification and selection of inflammatory cytokine-secreting T cell or a precursor thereof, based on the expression and/or modulation of melanoma cell adhesion molecule (MCAM) are disclosed.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: April 28, 2015
    Assignee: Val-Chum, Limited Partnership
    Inventors: Alexandre Prat, Romain Cayrol, Nathalie Arbour
  • Publication number: 20150110813
    Abstract: A method is provided for preventing rejection by an immune system of a recipient subject of a tissue transplanted from a donor subject into the recipient subject without the need for long-term administration of non-specific immunosuppressive drugs.
    Type: Application
    Filed: November 13, 2014
    Publication date: April 23, 2015
    Inventors: Hong Jiang, Leonard Chess
  • Publication number: 20150104467
    Abstract: Methods for treating and reducing the progression of neurodegenerative diseases, including, without limitation Alzheimer's disease, are provided. The methods of the invention reduce or deplete neutrophil/myeloid cells in the region of the brain by blocking neutrophil/myeloid cell adhesion and interaction with the vascular endothelium, by blocking infiltration of neutrophil/myeloid cells into the brain, by reducing motility of neutrophil/myeloid cells in the parenchyma, by blocking A?-induced activation and adhesion of neutrophil/myeloid cells, and/or by blocking A?-induced integrin activation, degranulation and/or ROS release in neutrophil/myeloid cells.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 16, 2015
    Inventor: Gabriela Constantin
  • Publication number: 20150098942
    Abstract: OX40 is a potent immune stimulating target. Provided herein are methods for the treatment of cancer patients using (3X40 agonists methods to predict clinical outcome of the treatment by correlation of the treatment and an increase in OX40-induced T cell proliferation.
    Type: Application
    Filed: February 6, 2012
    Publication date: April 9, 2015
    Applicant: Providence Health & Services - Oregon d/b/a Providence Portland Medical Center
    Inventors: Brendan Curti, Magdalena Kovacsovics-Bankowski, Ed Walker, Josh Walker, Andy Weinberg
  • Publication number: 20150098939
    Abstract: The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab.
    Type: Application
    Filed: August 29, 2014
    Publication date: April 9, 2015
    Applicant: SANOFI
    Inventors: Nicolas BAURIN, Francis BLANCHE, Beatrice CAMERON, Carsten CORVEY, Tarik DABDOUBI, Christian ENGEL, Peter FLORIAN, Ingo FOCKEN, Katja KROLL, Jochen KRUIP, Christian LANGE, Thomas LANGER, Martin LORENZ, Vincent MIKOL, Ercole Rao, Peter WONEROW
  • Publication number: 20150086616
    Abstract: Oral non-steroidal anti inflammatory drugs (NSAIDs) are not an effective treatment of Alzheimer's disease, because the brain dose is too low. Nasal delivery of NSAIDs such as ibuprofen, flurbiprofen, indomethacin, diclofenac, or naproxen, which inhibit the enzymes cyclooxygenase-1 (cox-1) and cox-2, are used to prevent and/or treat Alzheimer's disease, a low grade brain inflammation. The large amount of nasal NSAIDs (e.g., ibuprofen, flurbiprofen, indomethacin, diclofenac, or naproxen) that reaches the brain far exceeds that from an oral dose. Low-molecular-weight lipophilic drugs, such as ibuprofen, naproxen, indomethacin, diclofenac, and flurbiprofen, are readily absorbed into the brain by the intranasal route. Alzheimer's starts in the entorhinal cortex, which is closely connected to the olfactory nerves, and spreads anatomically in a defined pattern. Therefore, a nasal NSAID would readily reach the region of the brain where it acts therapeutically.
    Type: Application
    Filed: September 18, 2014
    Publication date: March 26, 2015
    Inventor: Steven Lehrer
  • Publication number: 20150086574
    Abstract: Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.
    Type: Application
    Filed: August 12, 2014
    Publication date: March 26, 2015
    Inventors: Holger Karsunky, Ying-Ping Jiang
  • Publication number: 20150086548
    Abstract: Embodiments of the present invention relate to compositions and methods of treating type 1 or type 2 diabetes mellitus or other conditions relating to metabolic dysfunction that may impact insulin secretion or action by administering an islet neogenesis agent in combination with an agent or agents that selectively inhibits, blocks or destroys the autoimmune destruction of pancreatic cells or agents that optimize function within existing islets in patients with type 1 diabetes, type 2 diabetes and related conditions.
    Type: Application
    Filed: September 5, 2014
    Publication date: March 26, 2015
    Inventor: Claresa S. Levetan
  • Publication number: 20150064196
    Abstract: The present disclosure provides hetero-bicyclic compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, hydrates, N-oxides, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by Bruton's tyrosine kinase (Btk) activity, The disclosure also relates to the process of preparation of compounds of Formula (I). These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of Bruton's tyrosine kinase (Btk), such as inflammatory and/or autoimmune disorder, cell proliferation, rheumatoid arthritis, psoriasis, psoriatic arthritis, transplant rejection, graft-versus-host disease, multiple sclerosis, inflammatory bowel disease, allergic diseases, asthma, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, B-cell malignancies, systemic lupus, erythematosus or other disorders.
    Type: Application
    Filed: October 8, 2014
    Publication date: March 5, 2015
    Inventors: Mahesh Thakkar, Summon Koul, Debnath Bhuniya, Kasim Mookhtiar, Santosh Kurhade, Yogesh Munot, Tanaji Mengawade, Bheemashankar A. Kulkarni
  • Publication number: 20150056167
    Abstract: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, andor lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.
    Type: Application
    Filed: September 4, 2014
    Publication date: February 26, 2015
    Inventors: Claresa S. Levetan, Loraine V. Upham
  • Publication number: 20150056186
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and an anti-Bcl-2 active agent for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Another aspect of the invention is a kit comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type II anti-CD20 antibody and an anti-Bcl-2 active agent.
    Type: Application
    Filed: March 27, 2014
    Publication date: February 26, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: THOMAS FRIESS, CHRISTIAN KLEIN, PAMELA STREIN, PABLO UMANA
  • Patent number: 8962806
    Abstract: The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
    Type: Grant
    Filed: December 29, 2008
    Date of Patent: February 24, 2015
    Assignees: Dana-Farber Cancer Institute, Inc., The Bingham and Women's Hospital
    Inventors: Wayne Marasco, Jianhua Sui, Quan Zhu, Thomas Kupper
  • Patent number: 8961976
    Abstract: The present invention provides peptides, and fragments thereof, and antibodies, or fragments thereof comprising the same, wherein the peptide comprises at least one amino acid substitution compared to wild type 5c8 antibody. The present invention also provides compositions and methods of treating CD154-related diseases or disorders in a subject.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: February 24, 2015
    Assignee: Biogen Idec Ma Inc.
    Inventors: Herman Van Vlijmen, Alexey Lugovskoy, Karl Hanf
  • Patent number: 8956615
    Abstract: T cell memory can persist in the absence of antigen. However, some memory cells by default are subject to signals accompanying periodic antigen exposure. OX40 is essential to the extent and persistence of Th2 memory when antigen is re-encountered. In an animal model of allergic asthma, inhibiting OX40/OX40L signaling during the secondary response to inhaled antigen suppressed lung inflammation. Inhibiting OX40 at the time of memory cell reactivation reduced the longevity of memory with further inflammation prevented upon tertiary encounter with antigen.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: February 17, 2015
    Assignee: La Jolla Institute for Allergy and Immunology
    Inventors: Michael Croft, Shahram Salek-Ardakani
  • Publication number: 20150044231
    Abstract: The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.
    Type: Application
    Filed: August 25, 2014
    Publication date: February 12, 2015
    Inventors: Kristian Kjaergaard, Soeren Lund, Stefan Zahn, Louise H. Zeuthen, Anker J. Hansen
  • Publication number: 20150044164
    Abstract: Novel methods for treating patients with autoimmune diseases are disclosed. The methods of the invention include first depleting circulating lymphocytes in the mammal, e.g., by administering anti-thymocyte antibody, and then, during the course of repopulation, administering to the mammal a therapeutically effective amount of latent TGF-? and/or another agent that promotes expansion of regulatory T cells. In certain aspects, the disclosed process results in improved kidney function and survival rates.
    Type: Application
    Filed: November 19, 2012
    Publication date: February 12, 2015
    Applicant: GENZYME CORPORATION
    Inventors: Johanne KAPLAN, John M. McPHERSON
  • Publication number: 20150044230
    Abstract: The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease.
    Type: Application
    Filed: August 20, 2014
    Publication date: February 12, 2015
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Vijay K. Kuchroo, Laurent Monney, Jason L. Gaglia, Edward A. Greenfield, Gordon J. Freeman, Hanspeter Waldner
  • Patent number: 8951518
    Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: February 10, 2015
    Assignees: Ono Pharmaceutical Co., Ltd.
    Inventors: Tasuku Honjo, Shiro Shibayama, Kazuhiko Takeda, Masayoshi Matsuo, Takao Yoshida, Masakazu Miyamoto
  • Publication number: 20150037278
    Abstract: The invention relates to a method for predicting an improved therapeutic benefit for an individual with a tumor load before initiating an immune therapy which is capable of activating immune cells against said tumor as well as to pharmaceutical compositions for use in this method.
    Type: Application
    Filed: May 16, 2012
    Publication date: February 5, 2015
    Applicants: Michael Stroehlein, Markus Heiss
    Inventors: Horst Lindhofer, Markus Heis, Michael Stroehlein
  • Patent number: 8945565
    Abstract: Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: February 3, 2015
    Assignees: Selexys Pharmaceuticals Corporation, Oklahoma Medical Research Foundation
    Inventors: Scott Rollins, Richard Alvarez, Russell Rother, Rodger P. McEver, Ziad S. Kawar
  • Patent number: 8945564
    Abstract: Stable liquid pharmaceutical compositions comprising an antagonist anti-CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and an amount of arginine-HCl sufficient to render the liquid composition near isotonic. The stable liquid antagonist anti-CD40 antibody-containing pharmaceutical compositions of the invention find use in methods for treating proliferative diseases and diseases having an autoimmune and/or inflammatory component.
    Type: Grant
    Filed: April 17, 2007
    Date of Patent: February 3, 2015
    Assignees: Novartis AG, Xoma Technology Ltd.
    Inventors: Xiaofeng Lu, Bao-Lu Chen, Kidisti Araya, Augustus Okhamafe
  • Publication number: 20150017185
    Abstract: The present invention provides a method for enhancing the immune function of a memory T cell which comprises the step of coinhibting signalling via an inhibitory receptor which regulates T cell exhaustion and via the p38 MAP kinase signalling pathway in the T cell, and a method for treating and/or preventing an immune condition in a subject, which comprises the step of enhancing the immune function of a memory T cell in the subject by such a method. There is also provided a pharmaceutical composition or kit comprising an agent capable of inhibiting signalling via an inhibitory receptor which regulates T cell exhaustion, such as PD-1, and an agent capable of inhibiting the p38 MAP kinase signalling pathway.
    Type: Application
    Filed: November 29, 2012
    Publication date: January 15, 2015
    Inventors: Arne Akbar, Sian Henson
  • Publication number: 20150017121
    Abstract: The invention relates to a combination medicament for treatment of malignant neoplastic disease. The combination medicament comprises an IL-12 polypeptide having a biological activity of IL-12 or a nucleic acid expression vector comprising a sequence encoding such IL-12 polypeptide, and a non-agonist CTLA-4 ligand or non-agonist PD-1 ligand, particularly an anti-CTLA-4 or anti-PD-1 immunoglobulin G.
    Type: Application
    Filed: October 10, 2012
    Publication date: January 15, 2015
    Applicant: UNIVERSITAT ZURICH
    Inventors: Burkhard Becher, Johannes Vom Berg
  • Publication number: 20150010496
    Abstract: Disclosed herein are ?-galactosylceramide (?-GalCer) analogs and compositions thereof, methods of activating invariant Natural Killer T (iNKT) cells using said analogs, methods of treating diseases by activating iNKT cells using said analogs, and combination therapy of said analogs.
    Type: Application
    Filed: November 30, 2012
    Publication date: January 8, 2015
    Inventors: Vincenzo Cerundolo, Gurdyal S. Besra, Liam Cox
  • Publication number: 20150010508
    Abstract: The present invention provides methods and kits for treating diseases and conditions associated with impaired pancreatic function. The present invention further provides methods of stimulating islet cell neogenesis and stimulating islet cell differentiation from progenitor cells.
    Type: Application
    Filed: July 21, 2014
    Publication date: January 8, 2015
    Inventors: Claresa S. Levetan, Loraine V. Upham